Interventions and Clinical Trials

In the News

Ifakara scientist explains why ending Tuberculosis requires better diagnostics

Ending tuberculosis through better diagnostics Author: Dr. Frederick Haraka, MD Yes, to end tuberculosis (TB), we need better diagnostic tools! TB is among the deadliest diseases in the world. In …

Study: 12% of people living with HIV in rural Tanzania have hypertension

Dar es Salaam, Tanzania (March 9, 2017). IHI Research Scientist Dr Kim Mwamelo presents findings of the study in Boston, US, last year at the Conference on Retroviruses and Opportunistic …

Recent Projects

Assessing the progress towards rabies elimination from Pemba Island, Tanzania

Rabies is a deadly disease endemic in dog populations across Africa. Although rabies can be eliminated through mass dog vaccination, there has been little investment in dog vaccination in Africa …

Engaging pastoralists in controlling malaria mosquitoes in their communities

The project is aimed at applying pastoralists’ knowledge to find water bodies during the dry season and accurately identify aquatic habitats that can be treated with larvicide pyriproxyfen (PPF) to …


The department conducts trials on drugs, diagnostics and vaccines for Tuberculosis (TB), HIV, Malaria and other diseases including respiratory pathogens,  zoonotic diseases, arboviruses, and various emerging and re-emerging infections. The department is supported by two laboratories with state of the art facilities at Ifakara and Bagamoyo Branches. The department is also expanding its portfolio to include non-communicable diseases, which are on the rise even in developing countries. Though we were previously working mostly on malaria, we have in recent years began work on development and testing of new TB drugs, given that what we have today have been in use for over 50 years. At our Chronic Diseases Clinic in Ifakara, we offer high quality HIV clinical care, while at the same time training researchers to improve the clinical care of HIV-infected people.  Moreover, IHI laboatories are continuously improving the diagnostic capacity, to serve IHI research projects and collaborators both within and outside the country. Our immunology department has grown in human capacity and equipment to analyze samples for different TB and malaria clinical trials.

In recent years scientists in the department have pioneered multiple innovative ways to assess vaccine candidates on malaria challenge study with infectious sporozoites. We are currently also providing technical support in other countries to start and implementing clinical trials. For example, we have a group now based in Equitorial Guinea supporting large-scale vaccine trial programs there. The department strives to strengthen the capacity to conduct clinical trials on infectious diseases including training IHI staff at Masters and PhD level. IHI is now firmly established as a dependable site where trials could be conducted in the future. The department staff are multidisplinary, consisting of statisticians, physicians, epidemiologists, public health specialists and social scientists.

Key Contacts

Head of Department

Deputy Heads of Department

Administrative Support


Evaluation of whole sporozoite vaccines for malaria elimination

Safety and immunogenicity of direct venus inoculation of Plasmodium falciparum sporozoite vaccine in adults, children and infants

Safety, immunogenicity and efficacy of intravenously administered attenuated Plasmodium falciparum sporozoite vaccine

Providers’ compliance to malaria treatment using Artemisinin-based combination therapy-ACTs in Tanzania

Evaluation of intravenous iron supplementation compared to oral supplementation among women with iron-deficient anemia

Zoonotic viral sharing among bats, primates and people in high-risk areas in Tanzania

Evaluation of Lopinavir-based anti-retroviral therapy for HIV-Infected children: a phase IIIb clinical trial in Ifakara

Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

Screening and treatment of cryptococcal meningitis in Kilombero and Ulanga districts in Tanzania

Kilombero and Ulanga antiretroviral cohort study (KIULARCO)

Tanzania lung health study: prevalence and risk of chronic obstructive pulmonary disease

Malaria in Pregnancy Preventive Alternative Drugs(MiPPAD)

Epidemiology and molecular monitoring of HIV drug resistance in Tanzania

© Ifakara Health Institute (IHI), 2016